Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057977 | 0.86 | CYP1A2 (0.42) | CHRM3CCR1OPRK1BCHECYP2C19 | |
| SCHEMBL5059796 | 0.80 | HPGD (0.46) | KMT2ACYP2C19 | |
| SCHEMBL5054383 | 0.78 | CYP2C19 (0.41) | KMT2ACYP2C19 | |
| SCHEMBL5054412 | 0.76 | HPGD (0.45) | KMT2ACYP2C19 | |
| SCHEMBL5057992 | 0.76 | CYP2C19 (0.44) | CYP2C19 | |
| SCHEMBL5053311 | 0.75 | TSHR (0.56) | CYP2C19 | |
| SCHEMBL1418773 | 0.74 | CYP2C19 (0.47) | CCR1BCHECYP2C19 | |
| SCHEMBL1418768 | 0.74 | CYP2C19 (0.47) | CCR1BCHECYP2C19 | |
| SCHEMBL5052964 | 0.73 | CETP (0.47) | CYP2C19 | |
| SCHEMBL5051132 | 0.72 | TSHR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |